Saturday, December 12, 2015

Ogre, Or Savvy Businessman ???

Martin Shkreli is once again provoking alarm with a plan to sharply increase the price of a decades-old drug for a serious infectious disease. This time the drug treats Chagas disease, a parasitic infection that can cause potentially lethal heart problems.

“It’s caused a lot of angst in the Chagas community,” said Dr. Sheba Meymandi, a professor at the University of California, Los Angeles, and director of a Chagas treatment center at Olive View-UCLA Medical Center. “Everyone’s in an uproar.”

The plan also is upsetting some organizations that supply drugs for neglected diseases because Mr. Shkreli has said he wants to take advantage of a federal program intended to encourage companies to develop such drugs. The program awards vouchers that can be sold to other companies for hundreds of millions of dollars.

Mr. Shkreli has said he hopes to obtain such a voucher by getting the Chagas disease drug approved by the Food and Drug Administration for sale in the United States. Critics say that it would be another case of the system being abused by awarding a voucher not for developing a new drug but merely for obtaining F.D.A. approval of a drug already used in tropical countries.

Mr. Shkreli, 32, a former hedge fund manager, declined to comment.

He set off a furor in September after his company, Turing Pharmaceuticals, acquired the rights to a 62-year-old drug for toxoplasmosis, another parasitic infection, and raised its price overnight to $750 a pill from $13.50.

Last month, Mr. Shkreli led an investor group that took control of a failing California biotechnology company, buying a majority of its shares on the open market at an average price of about $1.50 a share. The stock of the company, KaloBios Pharmaceuticals, now sells for about $28,  based in part on expectations that the company will prosper under Mr. Shkreli.

You can read the rest @

Mr. Shkreli is not doing anything illegal. In fact, he is living the new American Dream - buy low, sell high, and get filthy rich on the backs of the poor.

And let's face it, the medical and pharmaceutical industries are not in the business of being compassionate. They're in the business of making LOTS of money.

The US government could have prevented this, but instead they gave us the abomination known as ObamaDon'tCare.

Lucky us.

No comments:

Post a Comment